CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Penning, J. P.
Right arrow Articles by Baxter, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Penning, J. P.
Right arrow Articles by Baxter, A. D.

Canadian Journal of Anesthesia, Vol 35, 599-604, Copyright © 1988 by Canadian Anesthesiologists' Society

ARTICLES

Reversal of epidural morphine-induced respiratory depression and pruritus with nalbuphine

JP Penning, B Samson and AD Baxter
Department of Anaesthesia, Ottawa General Hospital, University of Ottawa, Ontario.

The effect of nalbuphine on the respiratory depression, pruritus and analgesia induced by epidural morphine was determined in a randomized, prospective, double-blind, placebo-controlled fashion. Twenty ASA physical status I women received 0.1 mg.kg-1 epidural morphine at induction of general anaesthesia for elective total abdominal hysterectomy. Group 1 (n = 14) received 0.3 mg.kg-1 nalbuphine intravenously six hours after the epidural morphine administration. Group 2 (n = 6) received saline. Prior to agent administration, six patients from the nalbuphine group and four patients from the saline group had respiratory depression indicated by a PaCO2 greater than 45 mmHg. After nalbuphine administration the PaCO2 (mean +/- SE) decreased from 49.5 +/- 1.2 mmHg to 42.5 +/- 0.7 mmHg (p less than 0.005) while there was no significant change after saline administration. Nine of the 14 patients receiving nalbuphine appeared to become more sedated, despite an improvement in ventilation. Pruritus was antagonized by 0.1 mg.kg-1 nalbuphine (p less than 0.006). There was no reversal of analgesia after administration of 0.3 mg.kg-1 nalbuphine.


This article has been cited by other articles:


Home page
 Canadian J. AnesthesiaHome page
N. Nakatsuka, S. C. Minogue, J. Lim, C. J. Montgomery, C. A. Court, S. Malherbe, Y. Csanyi-Fritz, R. A. Kearney, L. Phillips, K. Reid, et al.
Intravenous nalbuphine 50 {micro}g{middle dot}kg-1 is ineffective for opioid-induced pruritus in pediatrics: [La nalbuphine intraveineuse a 50 {micro}g{middle dot}kg-1 est inefficace contre le prurit induit par les opioides chez des enfants].
Can J Anesth, November 1, 2006; 53(11): 1103 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
T. Yaksh and D. J. Birnbach
Intrathecal Nalbuphine After Cesarean Delivery: Are We Ready?
Anesth. Analg., September 1, 2000; 91(3): 505 - 508.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the Canadian Anesthesiologists' Society.